Welcome to our dedicated page for Sangamo Therapeutics SEC filings (Ticker: SGMO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Genome-editing breakthroughs generate excitement—and lengthy disclosures. Sangamo Therapeutics’ risk factors span complex gene-editing platforms, trial data, and royalty-sharing with partners. If you’ve opened their 10-K and wondered, “Why is AAV vector safety buried on page 123?” you’re not alone. Stock Titan turns "Sangamo Therapeutics SEC filings explained simply" from wishful thinking into reality with AI-powered summaries that surface the questions investors actually ask.
Need the numbers fast? Our dashboard links every Sangamo Therapeutics quarterly earnings report 10-Q filing and delivers capsule revenue trends, cash-burn ratios, and pipeline spend in minutes. Drill into Form 4 details—"Sangamo Therapeutics insider trading Form 4 transactions"—and follow executives’ CRISPR-confidence in real time. AI tags each "Sangamo Therapeutics annual report 10-K simplified," highlights gene-editing milestones, and cross-references "Sangamo Therapeutics proxy statement executive compensation" so you can see how pay aligns with clinical progress. Even sudden study updates arrive instantly through "Sangamo Therapeutics 8-K material events explained."
Whether you’re modeling dilution risk or comparing partner economics, understanding Sangamo Therapeutics SEC documents with AI saves hours. Receive "Sangamo Therapeutics Form 4 insider transactions real-time" mobile alerts, launch side-by-side "Sangamo Therapeutics earnings report filing analysis," or track "Sangamo Therapeutics executive stock transactions Form 4" before the market reacts. With comprehensive coverage, expert commentary, and real-time EDGAR feeds, Stock Titan keeps genomic-medicine investors one step ahead—no molecular biology PhD required.
Gregory D. Davis, Head of Research & Technology and an officer of Sangamo Therapeutics, Inc. (SGMO), reported a deemed disposition of 723 shares of the issuer's common stock on 08/24/2025 under Form 4. The transaction code is F and was a mandatory tax-withholding surrender of shares underlying vested restricted stock units (RSUs) using the issuer's closing price on 08/22/2025 of $0.5863 per share; the withholding is treated as a disposition for reporting purposes and not an open-market sale. Following the transaction, the reporting person beneficially owns 201,222 shares. The filing discloses the schedule of remaining RSU vesting installments and notes vesting is subject to continuous service and potential acceleration per the 2018 Equity Incentive Plan.
Sangamo Therapeutics insider filing shows routine RSU vesting and tax-withholding disposition. On 08/24/2025 the reporting person, Scott B. Willoughby (SVP, Chief Legal Officer, Secretary and Director), had 1,434 shares disposed of at a price of $0.5863 per share to satisfy mandatory tax withholding related to RSUs that vested that day.
After the withholding disposition the reporting person beneficially owns 748,243 shares. The filing details scheduled vesting: 2,574 shares from a Feb 24, 2023 RSU grant (with remaining installments through Feb 24, 2026), 178,125 shares from a Jan 22, 2024 RSU grant vesting through Jan 22, 2026, and 120,000 shares from a Feb 25, 2025 RSU grant with one-quarter vesting on Feb 25, 2026 and the remainder in eight quarterly installments. All vesting is conditioned on Continuous Service and any applicable acceleration under the 2018 EIP.
Sangamo Therapeutics insider Prathyusha Duraibabu, SVP and Chief Financial Officer, reported a routine disposition on 08/24/2025 of 1,792 shares of common stock. The shares were surrendered to the company solely to satisfy mandatory tax withholding on RSUs using the closing price of $0.5863 per share on 08/22/2025. Following the transaction the reporting person beneficially owns 744,487 shares, which include multiple RSU grants that vest over time: installments from a 02/24/2023 grant, a 01/22/2024 grant, and a 02/25/2025 grant, each subject to continuous service and plan terms.
Sangamo Therapeutics insider Nathalie Dubois-Stringfellow reported a small disposition tied to RSU tax withholding and continues to hold a substantial equity stake. The Form 4 shows that on 08/24/2025 she surrendered 1,792 shares to the company for mandatory tax withholding at a price of $0.5863 per share related to vested restricted stock units under the 2018 Equity Incentive Plan.
After the withholding disposition, the reporting person beneficially owns 766,089 shares. The filing details the schedule of outstanding RSU grants and future vesting: remaining installments from a 2023 grant, a 2024 grant vesting through January 22, 2026, and a 2025 grant with a first vesting on February 25, 2026, all subject to continuous service and plan acceleration provisions.
Sangamo Therapeutics filed a Form S-8 to register an additional 14,000,000 shares of common stock to be issued pursuant to its Amended and Restated 2018 Equity Incentive Plan. The filing incorporates prior Form S-8 registrations for 19,131,725, 9,900,000, 7,900,000, 10,000,000 and 11,000,000 shares.
The submission relies on incorporation by reference to the company’s recent periodic reports and includes key exhibits such as the Amended Plan and legal opinions; corporate officers including the CEO and CFO signed the registration.
FAQ
What is the current stock price of Sangamo Therapeutics (SGMO)?
What is the market cap of Sangamo Therapeutics (SGMO)?
